Traders are rotating out of Shiba Inu as speculative chatter intensifies around Lightchain AI, driving its presale to new ...

Polygon is making waves with its latest technical announcements, capturing attention through planned upgrades and ecosystem ...

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in ...

Biogen shared Phase I trial results, highlighting the potential benefits of the SMA treatment while promoting its once-yearly ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared positive topline results from the ...

Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen ...

In a Phase I study, previously treated pediatric SMA patients exhibited reductions in a marker of neurodegeneration after salanersen treatment.

Discover the Crypto Presales Set to Transform Your Portfolio June 2025 is proving to be an electrifying month in the crypto ...